Please check your internet connection and try again.
## Clobazam (Oral Formulation)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It acts by enhancing the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABAA receptor, resulting in increased inhibitory effects.
### Primary Indications
* Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years and older.
* Other seizure types (off-label use, often as adjunctive therapy).
### Adult Dosing
* **Lennox-Gastaut Syndrome:**
* **Initiation:** 5 mg orally twice daily.
* **Maintenance:** Increase dose gradually by 5 mg to 10 mg every week. Target maintenance dose is typically 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily.
### Pediatric Dosing (2 years and older)
* **Lennox-Gastaut Syndrome:**
* **Initiation:** 2.5 mg orally twice daily.
* **Maintenance:** Increase dose gradually by 2.5 mg to 5 mg every week. Target maintenance dose is typically 5 mg to 10 mg twice daily.
* **Maximum Dose:** 10 mg twice daily for patients weighing less than 30 kg, and 20 mg twice daily for patients weighing 30 kg or more.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary.
* **Renal Impairment:** Use with caution. Dose reduction may be necessary.
* **Concomitant Medications:** Consider interactions (see Key Drug Interactions).
### Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory impairment.
* Severe hepatic impairment.
* Acute narrow-angle glaucoma.
### Adverse Effects
Common adverse effects include: somnolence, decreased appetite, constipation, aggression, drooling, irritability, pyrexia, fatigue, upper respiratory tract infection, vomiting, and ataxia. Serious adverse effects include: serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), suicidal behavior or ideation, withdrawal symptoms, and respiratory depression.
### Key Drug Interactions
* **CNS Depressants (alcohol, opioids, other sedatives):** Additive CNS depression.
* **CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
* **CYP2C19 Inducers (e.g., rifampin):** May decrease clobazam concentrations.
* **Stimulants:** May decrease the efficacy of stimulants.
### Monitoring
* Monitor for efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of respiratory depression.
* Monitor for signs of withdrawal if discontinuing therapy.
* Monitor for suicidal behavior or ideation.
### Clinical Pearls
* Clobazam should be used as adjunctive therapy.
* Taper slowly when discontinuing to avoid withdrawal symptoms.
* Patients and caregivers should be educated about the risk of serious skin reactions and instructed to seek immediate medical attention if a rash develops.
* Due to its long half-life, clobazam can accumulate, especially in elderly patients or those with hepatic or renal impairment.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and your institution's protocols before making any treatment decisions.*
